Results 61 to 70 of about 15,553 (191)

Necrotising Soft Tissue Infections: A Single Center's Case Series

International Wound Journal, Volume 23, Issue 3, March 2026.
ABSTRACT Necrotising soft tissue infection (NSTI) is a progressive disease with a time‐dependent prognosis; if not promptly treated, it can lead to significant morbidity as well as mortality. Early and aggressive surgical treatment is mandatory for appropriate management. This study reports the diagnostic and therapeutic pathway, surgical treatment and
Francesca Toia, Andrea Pio Cascino, Mara Franza, Marco Romeo, Antonino Speciale, Adriana Cordova, Massimiliano Tripoli   +6 more
wiley   +1 more source

Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam

Microbiology Spectrum
With the introduction of ceftazidime-avibactam worldwide, the antimicrobial activity of new β-lactam/β-lactamase inhibitors (BL/BLIs) needs to be investigated.
Min Seo Kang, Jin Yang Baek, Jae-Hoon Ko, Sun Young Cho, Keon Young Lee, Young Ho Lee, Jinyoung Yang, Tae Yeul Kim, Hee Jae Huh, Nam Yong Lee, Kyungmin Huh, Cheol-In Kang, Doo Ryeon Chung, Kyong Ran Peck   +13 more
doaj   +1 more source

Adverse Event Signals Associated with Beta-Lactamase Inhibitors: Disproportionality Analysis of USFDA Adverse Event Reporting System

Journal of Xenobiotics
Background: Beta-lactamase inhibitors (BLIs) are widely used with beta-lactam antibiotics to combat resistant infections, yet their safety profiles, especially for newer agents, remain underexplored.
Kannan Sridharan, Gowri Sivaramakrishnan
doaj   +1 more source

WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases [PDF]

, 2017
Background: Several diazabicyclooctanes (DBOs) are under development as inhibitors of Class A and C -lactamases. Inhibition of OXA (Class D) carbapenemases is variable, with those of Acinetobacter spp. remaining notably resistant. We describe a novel DBO,
Anna Vickers, Clinical and Laboratory Standards Institute, David M. Livermore, Neil Woodford, Shazad Mushtaq   +4 more
core   +1 more source

Ceftazidima-Avibactam

Revista Ciencia y Salud Integrando Conocimientos, 2021
Ceftazidima-avibactam es una combinación administrada por vía intravenosa, la cual posee actividad contra patógenos resistentes gram negativos como lo son por ejemplo las Pseudomonas aeruginosas y las enterobacterias resistentes a carbapenem.  Esta combinación está aprobada para el tratamiento de infecciones complicadas urinarias, infecciones ...
Maria Natalia Ugalde Solera, Fiorella María Mora Salazar   +1 more
openaire   +3 more sources

Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Molecular reversal strategies against antibiotic resistance act through three mechanisms: inhibiting resistance gene function, blocking horizontal gene transfer, and modulating host defense. Emerging technologies, such as CRISPR‐Cas gene editing, photodynamic therapy, nanotechnology, and ecological competition, further strengthen these approaches ...
Tianjiao Li, Fei Zeng, Jie Zhang, Yuangong Zhang, Wenjuan Yin   +4 more
wiley   +1 more source

The Rapid CarbaLux Combination Test to Uncover Bacterial Resistance and Heteroresistance Prior to Antibiotic Treatment

Diagnostics
Background/Objectives: In this proof-of-concept study, the objective was to evaluate the phenotypic CarbaLux combination rapid test in terms of guiding the therapy of infections caused by multidrug-resistant Gram-negative bacteria with carbapenemase ...
Hans Rudolf Pfaendler, Hans-Ulrich Schmidt   +1 more
doaj   +1 more source

Persistent Burkholderia cepacia Bacteremia in Reconstructive Surgery: Resistance to Ceftazidime/Avibactam and Co‐Trimoxazole With Risk of Infective Endocarditis—A Case Report

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Persistent Burkholderia cepacia bacteremia in soft tissue infections creates diagnostic and therapeutic challenges due to its resistance profile and potential for endovascular involvement. Early culture‐guided therapy, multidisciplinary coordination, and vigilance for complications, such as infective endocarditis, are essential for achieving ...
Chukwuka Elendu, Dependable C. Amaechi, Tochi C. Elendu, Emmanuel C. Amaechi, Ijeoma D. Elendu, Adaobi S. Ikedilo   +5 more
wiley   +1 more source

Cyclic Boronates Inhibit All Classes of β-Lactamase [PDF]

, 2017
β-Lactamase-mediated resistance is a growing threat to the continued use of β-lactam antibiotics. The use of the β-lactam-based serine-β-lactamase (SBL) inhibitors clavulanic acid, sulbactam, tazobactam, and, more recently, the non-β-lactam inhibitor ...
Brem, J, Cahill, ST, Cain, R, Fishwick, CWG, Lohans, CT, McDonough, MA, Mohammed, J, Oswin, HP, Schofield, CJ, Spencer, J, Wang, DY, Wareham, DW   +11 more
core   +5 more sources

A Selective Medium for Screening Ceftazidime/Avibactam Resistance in Carbapenem-Resistant Enterobacterales

Frontiers in Microbiology, 2022
Ceftazidime/avibactam (CZA) is an alternative antibiotic used for the treatment of infections caused by carbapenem-resistant Enterobacterales (CRE). However, the CZA-resistant CRE strains have been detected worldwide.
Weiliang Zeng, Wenli Liao, Wenli Liao, Yajie Zhao, Lingbo Wang, Hongyun Shu, Huaiyu Jia, Tao Chen, Ying Zhang, Tieli Zhou, Qing Wu   +10 more
doaj   +1 more source